Protagonist Therapeutics Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
45.27
2.3
(5.35%)
Volume:
1,000,897
52 week range:
27.00 - 60.60
Market Cap:
2.806B
Company Description:
Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.